Summit X, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
Summit X, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$12,892
-38.7%
10,925
-26.8%
0.00%
-20.0%
Q2 2023$21,044
-36.0%
14,925
-31.9%
0.01%
-44.4%
Q1 2023$32,888
-30.4%
21,925
-26.7%
0.01%
-35.7%
Q4 2022$47,282
+63.0%
29,925
+20.1%
0.01%
+55.6%
Q3 2022$29,000
-39.6%
24,925
-16.7%
0.01%
-35.7%
Q2 2022$48,0000.0%29,925
-3.2%
0.01%
+16.7%
Q1 2022$48,000
-38.5%
30,925
-3.1%
0.01%
-33.3%
Q4 2021$78,000
+8.3%
31,925
+10.4%
0.02%0.0%
Q3 2021$72,000
-12.2%
28,925
-0.3%
0.02%
-14.3%
Q2 2021$82,000
+9.3%
29,000
-9.4%
0.02%0.0%
Q1 2021$75,000
+36.4%
32,000
+3.2%
0.02%
+31.2%
Q4 2020$55,000
+2650.0%
31,000
+6.9%
0.02%
Q3 2020$2,000
-92.0%
29,0000.0%0.00%
-100.0%
Q2 2020$25,0000.0%29,000
-5.5%
0.01%
-25.0%
Q1 2020$25,000
+31.6%
30,700
+44.8%
0.01%
+71.4%
Q4 2019$19,000
+5.6%
21,200
+16.5%
0.01%0.0%
Q3 2019$18,00018,2000.01%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders